Erscheint 6 Ausgaben pro Jahr
ISSN Druckformat: 1040-8401
ISSN Online: 2162-6472
Indexed in
PART V. Modulation of Antitumor Vaccine Strategies
Preclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy
ABSTRAKT
Tumor-associated antigens (TAAs) are by definition either weakly immunogenic or functionally nonimmunogenic. Vaccine strategies have been designed to present TAAs to the immune system that may result in far greater activation of T cells than that occurring naturally in the host. These strategies include (1) placing the gene coding for the tumor antigen into poxvirus vectors as a transgene; (2) using diversified prime-and-boost vaccine strategies employing two different types of poxvirus vectors; (3) using T−cell costimulation; and (4) using cytokines, including GM−CSF, as biologic adjuvants. Preclinical studies have been performed comparing the effects on induction of antigen-specific CD8 and CD4 T−cell responses using recombinant poxvirus vectors containing transgenes for a TAA and costimulatory molecules B7−1, ICAM−1, and LFA−3 (designated TRICOM). Antigen-specific T−cell responses were greatest in the group receiving the CEA-TRICOM vaccines and were shown to correlate with survival. We have now completed the first clinical trials with poxvirus vectors containing TRICOM, using the TAAs PSA, CEA, and MUC−1. In addition, clinical studies combining vaccines with radiation therapy, chemotherapy, and second-line hormone therapy have provided preliminary evidence of prolongation of time to disease progression and antigen cascade postvaccination.
-
Tang Choon-Kit, Katsara Maria, Apostolopoulos Vasso, Strategies used for MUC1 immunotherapy: human clinical studies, Expert Review of Vaccines, 7, 7, 2008. Crossref
-
Soares Kevin C., Zheng Lei, Edil Barish, Jaffee Elizabeth M., Vaccines for Pancreatic Cancer, The Cancer Journal, 18, 6, 2012. Crossref
-
Bright Jennifer D, Schultz Heather N, Byrne Jennifer A, Bright Robert K, Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen, OncoImmunology, 2, 7, 2013. Crossref
-
Caspi Rachel R., Immunotherapy of autoimmunity and cancer: the penalty for success, Nature Reviews Immunology, 8, 12, 2008. Crossref
-
Schlom Jeffrey, The MUC1-C oncoprotein as a target in hematologic malignancies, Cancer Biology & Therapy, 10, 5, 2010. Crossref
-
Salman Bulent, Zhou Donger, Jaffee Elizabeth M, Edil Barish H, Zheng Lei, Vaccine therapy for pancreatic cancer, OncoImmunology, 2, 12, 2013. Crossref
-
LIMBACH K. J., RICHIE T. L., Viral vectors in malaria vaccine development, Parasite Immunology, 31, 9, 2009. Crossref
-
Fokas Emmanouil, O'Neill Eric, Gordon-Weeks Alex, Mukherjee Somnath, McKenna W. Gillies, Muschel Ruth J., Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1855, 1, 2015. Crossref
-
Shumway Nathan M., Ibrahim Nuhad, Ponniah Sathibalan, Peoples George E., Murray James L., Therapeutic Breast Cancer Vaccines, BioDrugs, 23, 5, 2009. Crossref
-
Kaliberov Sergey A., Buchsbaum Donald J., Cancer Treatment with Gene Therapy and Radiation Therapy, in Applications of viruses for cancer therapy, 115, 2012. Crossref
-
Adamina Michel, Rosenthal Rachel, Weber Walter P, Frey Daniel M, Viehl Carsten T, Bolli Martin, Huegli Rolf W, Jacob Augustinus L, Heberer Michael, Oertli Daniel, Marti Walter, Spagnoli Giulio C, Zajac Paul, Intranodal Immunization With a Vaccinia Virus Encoding Multiple Antigenic Epitopes and Costimulatory Molecules in Metastatic Melanoma, Molecular Therapy, 18, 3, 2010. Crossref
-
Amedei Amedeo, Niccolai Elena, Prisco Domenico, Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy, Human Vaccines & Immunotherapeutics, 10, 11, 2014. Crossref
-
Thakur Archana, Vaishampayan Ulka, Lum Lawrence, Immunotherapy and Immune Evasion in Prostate Cancer, Cancers, 5, 4, 2013. Crossref
-
Tran Lucile, Judor Jean-Paul, Gauttier Vanessa, Geist Michel, Hoffman Chantal, Rooke Ronald, Vassaux Georges, Conchon Sophie, The Immunogenicity of the Tumor-Associated Antigenα-Fetoprotein Is Enhanced by a Fusion with a Transmembrane Domain, Journal of Biomedicine and Biotechnology, 2012, 2012. Crossref
-
Chandra S., Pavlick A.C., Kaufman H.L., Vaccines against Cancer, in Reference Module in Biomedical Sciences, 2014. Crossref
-
Drake Charles G., Update on Prostate Cancer Vaccines, The Cancer Journal, 17, 5, 2011. Crossref
-
Speiser Daniel E., Romero Pedro, Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity, Seminars in Immunology, 22, 3, 2010. Crossref
-
Xu Menglin, Wang Diane C., Wang Xiangdong, Zhang Yong, Correlation between mucin biology and tumor heterogeneity in lung cancer, Seminars in Cell & Developmental Biology, 64, 2017. Crossref
-
Stroopinsky Dina, Kufe Donald, Avigan David, MUC1 in hematological malignancies, Leukemia & Lymphoma, 57, 11, 2016. Crossref
-
Wong Karrie K., Li WeiWei Aileen, Mooney David J., Dranoff Glenn, Advances in Therapeutic Cancer Vaccines, in Tumor Immunology, 130, 2016. Crossref
-
Schlom Jeffery, Gulley James L., Hodge James W., Vaccines and Immunostimulants, in Holland-Frei Cancer Medicine, 2017. Crossref
-
Zheng Lei, Jaffee Elizabeth M., Vaccine Therapy and Immunotherapy for Pancreatic Cancer, in Pancreatic Cancer, 2017. Crossref
-
Zheng Lei, Jaffee Elizabeth M., Vaccine Therapy and Immunotherapy for Pancreatic Cancer, in Pancreatic Cancer, 2018. Crossref
-
Tian Jing-Yan, Guo Feng-Jun, Zheng Guo-You, Ahmad Aamir, Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities, Carcinogenesis, 39, 3, 2018. Crossref
-
Venturini Nicholas J., Drake Charles G., Immunotherapy for Prostate Cancer, Cold Spring Harbor Perspectives in Medicine, 9, 5, 2019. Crossref
-
Kumbhari Adarsh, Kim Peter S., Lee Peter P., Optimisation of anti-cancer peptide vaccines to preferentially elicit high-avidity T cells, Journal of Theoretical Biology, 486, 2020. Crossref
-
Tabi Zsuzsanna, Cancer Vaccines, in Pharmaceutical Perspectives of Cancer Therapeutics, 2009. Crossref
-
Tekkesin Nilgun, Tetik Sermin, Therapeutic vaccines for pancreatic cancer, in Theranostic Approach for Pancreatic Cancer, 2019. Crossref
-
Zheng Lei, Jaffee Elizabeth M., Vaccine Therapy and Immunotherapy for Pancreatic Cancer, in Pancreatic Cancer, 2010. Crossref
-
Principe Daniel R., Korc Murray, Kamath Suneel D., Munshi Hidayatullah G., Rana Ajay, Trials and tribulations of pancreatic cancer immunotherapy, Cancer Letters, 504, 2021. Crossref
-
Movassaghi Miyad, Chung Rainjade, Anderson Christopher B., Stein Mark, Saenger Yvonne, Faiena Izak, Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances, Cancers, 13, 19, 2021. Crossref
-
Arlen Philip M, Mohebtash Mahsa, Madan Ravi A, Gulley James L, Promising novel immunotherapies and combinations for prostate cancer, Future Oncology, 5, 2, 2009. Crossref
-
Current World Literature, Current Opinion in Obstetrics & Gynecology, 21, 1, 2009. Crossref
-
Cheever Martin A., Schlom Jeffrey, Weiner Louis M., Lyerly H. Kim, Disis Mary L., Greenwood Addison, Grad Oren, Nelson William G., Translational Research Working Group Developmental Pathway for Immune Response Modifiers, Clinical Cancer Research, 14, 18, 2008. Crossref
-
Slovin Susan F., Immunotherapeutic Approaches in Prostate Cancer: Combinations and Clinical Integration, American Society of Clinical Oncology Educational Book, 35, 2015. Crossref
-
Drake Charles G., Preoperative Immunotherapy for Prostate Cancer: From Bench to Bedside, in Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers, 2022. Crossref
-
Drake Charles G., Immunotherapy for Prostate Cancer: Walk, Don't Run, Journal of Clinical Oncology, 27, 25, 2009. Crossref
-
Earl Patricia L., Americo Jeffrey L., Wyatt Linda S., Espenshade Ondraya, Bassler Jocelyn, Gong Kathy, Lin Shuling, Peters Elizabeth, Rhodes Lowrey, Spano Yvette Edghill, Silvera Peter M., Moss Bernard, Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus, Proceedings of the National Academy of Sciences, 105, 31, 2008. Crossref
-
Boehm Amanda L., Higgins Jack, Franzusoff Alex, Schlom Jeffrey, Hodge James W., Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations, Cancer Immunology, Immunotherapy, 59, 3, 2010. Crossref
-
Schweizer Michael T., Drake Charles G., Immunotherapy for prostate cancer: recent developments and future challenges, Cancer and Metastasis Reviews, 33, 2-3, 2014. Crossref
-
Kufe Donald W., Mucins in cancer: function, prognosis and therapy, Nature Reviews Cancer, 9, 12, 2009. Crossref
-
Zhang Weijun, Zhang Tong, Turk Mary-Jo, Usherwood Edward J., A persistent virus vector confers superior anti-tumor immunity, compared with a non-persistent vector, Cancer Immunology, Immunotherapy, 59, 5, 2010. Crossref